Hahn Joins the Board of Directors at Soleno Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 13 2025
0mins
Appointment Announcement: Soleno Therapeutics has appointed Mark Hahn as an independent director to its Board of Directors and a member of its Audit Committee.
Board Expansion: With Hahn's addition, the Soleno Board now consists of seven members.
Previous Experience: Before joining Soleno, Hahn was the Chief Financial Officer at Verona Pharma.
Industry Background: Hahn brings extensive experience in biopharmaceutical finance to his new role on the board.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.950
Low
106.00
Averages
118.50
High
145.00
Current: 41.950
Low
106.00
Averages
118.50
High
145.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
